Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells

Oncotarget

Volumn 7, Issue 19, 2016, Pages 27158-27175

  Wu, Qiong ^a   Sharma, Soni ^b   Cui, Hang ^a,c   LeBlanc, Scott E ^a   Zhang, Hong ^a   Muthuswami, Rohini ^b   Nickerson, Jeffrey A ^a   Imbalzano, Anthony N ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c Biotech Pharmaceuticals Co Ltd   (China)

Author keywords

Breast cancer; BRG1; Drug transporters; Epigenetics; SWI SNF

Indexed keywords

BRG1 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; NEOMYCIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DNA HELICASE; ENZYME INHIBITOR; NUCLEAR PROTEIN; SMARCA4 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ABCB1 GENE; ABCC11 GENE; ABCC2 GENE; ABCG1 GENE; ABCG2 GENE; ARTICLE; BREAST CANCER CELL LINE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RETENTION; DRUG TREATMENT FAILURE; ENZYME INHIBITION; GENE; GENE INDUCTION; HUMAN; HUMAN CELL; IC50; MOLECULARLY TARGETED THERAPY; PROMOTER REGION; PROTEIN DNA BINDING; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PROCEDURES; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA HELICASES; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; NUCLEAR PROTEINS; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84968779430     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8384     Document Type: Article

References (99)

1. Barinaga M. From bench top to bedside. Science. 1997; 278:1036-1039.
2. Gilman A and Philips FS. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science. 1946; 103:409-415.
3. Cutts JH, Beer CT and Noble RL. Biological properties of Vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. Cancer Res. 1960; 20:1023-1031.
4. Nabholtz JM and Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol. 2001; 28:1-12.
5. Pastan II and Kreitman RJ. Immunotoxins for targeted cancer therapy. Adv Drug Deliv Rev. 1998; 31:53-88.
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R and Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-1042.
7. Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999; 17:94-95.
8. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5:219-234.
9. Garraway LA and Janne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2012; 2:214-226.
10. Lackner MR, Wilson TR and Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 2012; 8:999-1014.
11. Gottesman MM and Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006; 580:998-1009.
12. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13:714-726.
13. Juliano RL and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976; 455:152-162.
14. Ueda K, Cardarelli C, Gottesman MM and Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987; 84:3004-3008.
15. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986; 47:381-389.
16. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P and Housman DE. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989; 9:1346-1350.
17. Lothstein L, Hsu SI, Horwitz SB and Greenberger LM. Alternate overexpression of two P-glycoprotein [corrected] genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem. 1989; 264:16054-16058.
18. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992; 8:67-113.
19. Moitra K and Dean M. Evolution of ABC transporters by gene duplication and their role in human disease. Biol Chem. 2011; 392:29-37.
20. Keppler D. (2011). Multidrug Resistance Proteins (MRPs, ABCCs): Importance for Pathophysiology and Drug Therapy. In: Fromm MF and Kim RB, eds. Drug Transporters: Springer Berlin Heidelberg), pp. 299-323.
21. Nies AT and Lang T. (2014). Multidrug Resistance Proteins of the ABCC Subfamily. In: You G and Morris ME, eds. Drug Transporters: Molecular characterization and role in drug disposition. (Hoboken, NJ: John Wiley & Sons, Inc.), pp. 161-185.
22. Slot AJ, Molinski SV and Cole SP. Mammalian multidrugresistance proteins (MRPs). Essays Biochem. 2011; 50:179-207.
23. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M and Bates SE. ABCG2: a perspective. Adv Drug Deliv Rev. 2009; 61:3-13.
24. Khavari PA, Peterson CL, Tamkun JW, Mendel DB and Crabtree GR. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature. 1993; 366:170-174.
25. Muchardt C and Yaniv M. A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor. EMBO J. 1993; 12:4279-4290.
26. Wang W, Cote J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL and Crabtree GR. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 1996; 15:5370-5382.
27. Bai J, Mei P, Zhang C, Chen F, Li C, Pan Z, Liu H and Zheng J. BRG1 is a prognostic marker and potential therapeutic target in human breast cancer. PLoS One. 2013; 8:e59772.
28. Cohet N, Stewart KM, Mudhasani R, Asirvatham AJ, Mallappa C, Imbalzano KM, Weaver VM, Imbalzano AN and Nickerson JA. SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells. J Cell Physiol. 2010; 223:667-678.
29. de la Serna IL, Ohkawa Y, Higashi C, Dutta C, Osias J, Kommajosyula N, Tachibana T and Imbalzano AN. The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes. J Biol Chem. 2006; 281:20233-20241.
30. Ho L and Crabtree GR. Chromatin remodelling during development. Nature. 2010; 463:474-484.
31. Naidu SR, Love IM, Imbalzano AN, Grossman SR and Androphy EJ. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene. 2009; 28:2492-2501.
32. Wu JI. Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. Acta Biochim Biophys Sin (Shanghai). 2012; 44:54-69.
33. Wu Q, Madany P, Akech J, Dobson JR, Douthwright S, Browne G, Colby JL, Winter GE, Bradner JE, Pratap J, Sluder G, Bhargava R, Chiosea SI, van Wijnen AJ, Stein JL, Stein GS, et al. The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. J Cell Physiol. 2015; 230:2683-2694.
34. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK and Kim CF. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature. 2015; 520:239-242.
35. Liu X, Tian X, Wang F, Ma Y, Kornmann M and Yang Y. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. Eur J Cancer. 2014; 50:2251-2262.
36. Oakman C, Viale G and Di Leo A. Management of triple negative breast cancer. Breast. 2010; 19:312-321.
37. Brenton JD, Carey LA, Ahmed AA and Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of clinical oncology. 2005; 23:7350-7360.
38. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical cancer research. 2007; 13:4429-4434.
39. Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, Neven P, Janssens H, Deraedt K, Moerman P, Van Calster B, Christiaens MR, Paridaens R and Wildiers H. Triple negative breast cancer: clinical characteristics in the different histological subtypes. Breast. 2013; 22:761-766.
40. Livasy CA. Triple-Negative Breast Carcinoma. Surg Pathol Clin. 2009; 2:247-261.
41. The-Cancer-Genome-Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61-70.
42. Cory AH, Owen TC, Barltrop JA and Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991; 3:207-212.
43. Fedorov O, Castex J, Tallant C, Owen DR, Martin S, Aldeghi M, Monteiro O, Filippakopoulos P, Picaud S, Trzupek JD, Gerstenberger BS, Bountra C, Willmann D, Wells C, Philpott M, Rogers C, et al. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Science advances. 2015; 1:e1500723.
44. Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, Heffernan TP, Marszalek JR, Toniatti C, et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF mutant cancers: Insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res. 2015; 18:3865-3878
45. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65:55-63.
46. Dutta P, Tanti GK, Sharma S, Goswami SK, Komath SS, Mayo MW, Hockensmith JW and Muthuswami R. Global epigenetic changes induced by SWI2/SNF2 inhibitors characterize neomycin-resistant mammalian cells. PLoS One. 2012; 7:e49822.
47. Muthuswami R, Mesner LD, Wang D, Hill DA, Imbalzano AN and Hockensmith JW. Phosphoaminoglycosides inhibit SWI2/SNF2 family DNA-dependent molecular motor domains. Biochemistry. 2000; 39:4358-4365.
48. Chiba H, Muramatsu M, Nomoto A and Kato H. Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucleic acids research. 1994; 22:1815-1820.
49. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53:615-627.
50. Gottesman MM, Fojo T and Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2:48-58.
51. Vtorushin SV, Khristenko KY, Zavyalova MV, Perelmuter VM, Litviakov NV, Denisov EV, Dulesova AY and Cherdyntseva NV. The phenomenon of multi-drug resistance in the treatment of malignant tumors. Exp Oncol. 2014; 36:144-156.
52. Hlavac V, Brynychova V, Vaclavikova R, Ehrlichova M, Vrana D, Pecha V, Kozevnikovova R, Trnkova M, Gatek J, Kopperova D, Gut I and Soucek P. The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013; 14:515-529.
53. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG and Kruh GD. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl) adenine. J Biol Chem. 2003; 278:29509-29514.
54. Oguri T, Bessho Y, Achiwa H, Ozasa H, Maeno K, Maeda H, Sato S and Ueda R. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther. 2007; 6:122-127.
55. Minegaki T, Takara K, Hamaguchi R, Tsujimoto M and Nishiguchi K. Factors affecting the sensitivity of humanderived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett. 2013; 5:427-434.
56. Cui Y, Konig J, Buchholz JK, Spring H, Leier I and Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999; 55:929-937.
57. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M and Lage H. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res. 2006; 12:7149-7158.
58. Litviakov NV, Cherdyntseva NV, Tsyganov MM, Denisov EV, Garbukov EY, Merzliakova MK, Volkomorov VV, Vtorushin SV, Zavyalova MV, Slonimskaya EM and Perelmuter VM. Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response. Cancer Chemother Pharmacol. 2013; 71:153-163.
59. Folmer Y, Schneider M, Blum HE and Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 2007; 14:875-884.
60. Yao J, Feng FY, Lin C, Zhang XY, Fu M, Liang X and Yang Y. [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line]. Zhonghua Zhong Liu Za Zhi. 2005; 27:721-726.
61. Zhou J, Wang CY, Liu T, Wu B, Zhou F, Xiong JX, Wu HS, Tao J, Zhao G, Yang M and Gou SM. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J Gastroenterol. 2008; 14:925-930.
62. Meng X, Wang G, Guan R, Jia X, Gao W, Wu J, Yu J, Liu P, Yu Y, Sun W, Dong H and Fu S. Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-smallcell lung cancer cells. Pharmacogenomics. 2015; 16:23-34.
63. Subhani S, Jayaraman A and Jamil K. Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer. Biomed Pharmacother. 2015; 71:37-45.
64. Xu JW, Li QQ, Tao LL, Cheng YY, Yu J, Chen Q, Liu XP and Xu ZD. Involvement of EGFR in the promotion of malignant properties in multidrug resistant breast cancer cells. Int J Oncol. 2011; 39:1501-1509.
65. Li YT, Chua MJ, Kunnath AP and Chowdhury EH. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticlefacilitated delivery of target siRNAs. Int J Nanomedicine. 2012; 7:2473-2481.
66. Sprouse AA and Herbert BS. Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxelresistant MDA-MB-231 breast cancer cells. Anticancer Res. 2014; 34:5363-5374.
67. Euskirchen GM, Auerbach RK, Davidov E, Gianoulis TA, Zhong G, Rozowsky J, Bhardwaj N, Gerstein MB and Snyder M. Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet. 2011; 7:e1002008.
68. Rosenbloom KR, Dreszer TR, Pheasant M, Barber GP, Meyer LR, Pohl A, Raney BJ, Wang T, Hinrichs AS, Zweig AS, Fujita PA, Learned K, Rhead B, Smith KE, Kuhn RM, Karolchik D, et al. ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res. 2010; 38:D620-625.
69. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two populationbased cohorts. Breast Cancer Res. 2005; 7:R953-964.
70. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D and Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365:671-679.
71. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat. 2009; 116:303-309.
72. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET and Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102:13550-13555.
73. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98:262-272.
74. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H and Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68:5405-5413.
75. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10:529-541.
76. Thomas CE, Ehrhardt A and Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003; 4:346-358.
77. Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012; 55:9831-9837.
78. Barbieri I, Cannizzaro E and Dawson MA. Bromodomains as therapeutic targets in cancer. Brief Funct Genomics. 2013; 12:219-230.
79. Horn PJ and Peterson CL. The bromodomain: a regulator of ATP-dependent chromatin remodeling? Front Biosci. 2001; 6:D1019-1023.
80. Mujtaba S, Zeng L and Zhou MM. Structure and acetyllysine recognition of the bromodomain. Oncogene. 2007; 26:5521-5527.
81. Trotter KW, Fan HY, Ivey ML, Kingston RE and Archer TK. The HSA domain of BRG1 mediates critical interactions required for glucocorticoid receptor-dependent transcriptional activation in vivo. Mol Cell Biol. 2008; 28:1413-1426.
82. Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, Minder JL, Mercan F, Wang E, Eckersley-Maslin MA, Campbell AE, Kawaoka S, Shareef S, Zhu Z, Kendall J, Muhar M, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes & development. 2013; 27:2648-2662.
83. Trotter KW and Archer TK. Reconstitution of glucocorticoid receptor-dependent transcription in vivo. Mol Cell Biol. 2004; 24:3347-3358.
84. Sentani K, Oue N, Kondo H, Kuraoka K, Motoshita J, Ito R, Yokozaki H and Yasui W. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology: journal of immunopathology, molecular and cellular biology. 2001; 69:315-320.
85. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C and Li B. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. The Prostate. 2007; 67:203-213.
86. Saladi SV, Keenen B, Marathe HG, Qi H, Chin KV and de la Serna IL. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness. Molecular cancer. 2010; 9:280.
87. Watanabe T, Semba S and Yokozaki H. Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells. British journal of cancer. 2011; 104:146-154.
88. Lin H, Wong RP, Martinka M and Li G. BRG1 expression is increased in human cutaneous melanoma. The British journal of dermatology. 2010; 163:502-510.
89. Hohmann AF and Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends in genetics: TIG. 2014; 30:356-363.
90. Oike T, Ogiwara H, Amornwichet N, Nakano T and Kohno T. Chromatin-regulating proteins as targets for cancer therapy. Journal of radiation research. 2014; 55:613-628.
91. Marquez SB, Thompson KW, Lu L and Reisman D. Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation. Frontiers in oncology. 2014; 4:372.
92. Helming KC, Wang X and Roberts CW. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer cell. 2014; 26:309-317.
93. Cai SF, Chen CW and Armstrong SA. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. Molecular cell. 2015; 60:561-570.
94. Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015; 14:29-44.
95. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN and Gottesman MM. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004; 6:129-137.
96. Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID, Raats J and Burgess LJ. A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol. 2009; 64:763-768.
97. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T and Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996; 98:1544-1549.
98. Imbalzano KM, Cohet N, Wu Q, Underwood JM, Imbalzano AN and Nickerson JA. Nuclear shape changes are induced by knockdown of the SWI/SNF ATPase BRG1 and are independent of cytoskeletal connections. PLoS One. 2013; 8:e55628.
99. de la Serna IL, Ohkawa Y, Berkes CA, Bergstrom DA, Dacwag CS, Tapscott SJ and Imbalzano AN. MyoD targets chromatin remodeling complexes to the myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol. 2005; 25:3997-4009.